Table_1_Prognostic Value of Preoperative Hemoglobin Levels for Long-Term Outcomes of Acute Type B Aortic Dissection Post-thoracic Endovascular Aortic Repair.DOCX
Background and Aims: There is scant information available about the prognostic value of preoperative hemoglobin (Hb) levels on the long-term outcomes of acute type B aortic dissection (ABAD) following thoracic endovascular aortic repair (TEVAR).
Methods: A retrospective analysis of consecutive patients from 2010 to 2018 regarding the relationship between Hb level and long-term outcomes was conducted. The primary endpoint was all-cause mortality. Major adverse cardiovascular events (MACEs) included all-cause death, recurrent ruptures, and secondary procedures.
Results: In total, 391 subjects treated by TEVAR were enrolled, with a mean age of 57.1 ± 12.0 years; 79.5% of them were male. Cox multivariate analysis showed that the preoperative Hb level was independently associated with all-cause death [adjusted hazard ratio (HR) 0.797 (per 1 g/dl), 95% confidence interval (CI) 0.693–0.918, p = 0.002] and MACEs (adjusted HR 0.795, 95% CI 0.672–0.871, p = 0.000). The area under the receiver operating characteristic curve of Hb for all-cause death and MACEs were 0.617 (95% CI 0.548–0.687, p = 0.008) and 0.617 (95% CI 0.551–0.684, p = 0.005), respectively. In the linear trend test, Hb concentration was significantly related to all-cause mortality (p for trend = 0.001) and MACEs (p for trend = 0.000). Moreover, in Kaplan–Meier analysis, lower Hb levels (< 12 g/dl) were significantly different from higher Hb (≥12 g/dl) levels for both all-cause death (log-rank p = 0.001) and MACEs (log-rank p = 0.001). Similar results were found when assessing the prognostic value of red blood cell count and anemia.
Conclusions: Preoperative Hb may serve as a prognostic marker for long-range adverse outcomes for ABAD patients post-TEVAR.
History
References
- https://doi.org//10.1378/chest.117.5.1271
- https://doi.org//10.1161/CIRCULATIONAHA.112.000483
- https://doi.org//10.1093/eurheartj/ehu281
- https://doi.org//10.1161/CIRCULATIONAHA.117.031264
- https://doi.org//10.1161/CIRCULATIONAHA.110.965756
- https://doi.org//10.1161/HYPERTENSIONAHA.109.143131
- https://doi.org//10.1016/j.amjcard.2014.03.023
- https://doi.org//10.11909/j.issn.1671-5411.2017.01.011
- https://doi.org//10.18632/oncotarget.18105
- https://doi.org//10.1016/j.jacc.2007.12.015
- https://doi.org//10.1007/s00380-013-0354-x
- https://doi.org//10.1016/j.ajem.2016.03.067
- https://doi.org//10.1097/MD.0000000000018241
- https://doi.org//10.1016/j.atherosclerosis.2014.07.002
- https://doi.org//10.1016/j.ejim.2016.09.011
- https://doi.org//10.1016/j.jstrokecerebrovasdis.2018.01.026
- https://doi.org//10.1016/S0140-6736(18)32555-8
- https://doi.org//10.1177/1538574417697211
- https://doi.org//10.1093/eurheartj/ehy339
- https://doi.org//10.1186/s12889-015-2671-8
- https://doi.org//10.1161/01.CIR.0000162477.70955.5F
- https://doi.org//10.1016/j.jacc.2004.04.047
- https://doi.org//10.1161/CIRCULATIONAHA.106.653501
- https://doi.org//10.1161/CIRCINTERVENTIONS.113.000409
- https://doi.org//10.1161/01.CIR.0000052622.51963.FC
- https://doi.org//10.1016/j.jvs.2018.05.233
- https://doi.org//10.1161/CIR.0b013e3181d4739e
- https://doi.org//10.1016/j.athoracsur.2012.04.042
- https://doi.org//10.1016/S0735-1097(02)01854-5
- https://doi.org//10.1016/j.ejvs.2008.12.002
- https://doi.org//10.1161/CIRCULATIONAHA.107.698977
- https://doi.org//10.1016/j.jvs.2014.10.106
- https://doi.org//10.1378/chest.116.5.1233
- https://doi.org//10.1016/j.athoracsur.2010.11.078
CC BY 4.0